FibroGen Inc
(MEX:FGEN)
MXN
6.4
-0.01 (-0.16%)
Market Cap: 598.78 Mil
Enterprise Value: 711.97 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 44/100 FibroGen Inc at Citi BioPharma Conference (Virtual) Transcript
Sep 09, 2020 / 08:15PM GMT
Release Date Price:
MXN908
(+0.89%)
Joel Lawrence Beatty
Citigroup Inc., Research Division - VP & Analyst
Hi, everyone. Thanks for joining the session with FibroGen. I'm pleased to have with us the CEO, Enrique Conterno. Enrique, thanks for joining us today.
Enrique A. Conterno
FibroGen, Inc. - CEO & Director
No, thank you very much, Joe. I very much appreciate the invitation. Look forward to discussing a number of topics.
Joel Lawrence Beatty
Citigroup Inc., Research Division - VP & Analyst
Yes. Great. So I guess, I think a lot of viewers are going to be familiar with FibroGen, but some may not. So could you begin with an overview of what the key areas of focus are for FibroGen?
Enrique A. Conterno
FibroGen, Inc. - CEO & Director
Sure. So FibroGen is a company very much based in science. We've been able to progress 2 key products, one of them, roxadustat. The second one, pamrevlumab, which are very much in late stages. Roxa has already been commercialized in China and Japan and
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot